CLAIMS

1. A compound, or a pharmaceutically acceptable salt or solvate thereof, having the formula:



;

wherein

Z is N or C(R^8);

R^{10} is -L^7-R^7;

L^7 is a bond, -O-, -N(R^{14})-, -C(O)-, -S-, -S(O)$_2$-, -S(O)-, C_{1-4}alkyl, or 2-4 membered heteroalkyl linker, wherein the C_{1-4}alkyl and 2-4 membered heteroalkyl linker are each optionally substituted with one, two or three R^{20a};

R^7 is 

;

W^1 and W^3 are independently selected from N(R^1), N(R^4), C(R^1)(R^1), C(R^1)(R^4), C(R^4)(R^4), C(O), S, O, S(O), and S(O)$_2$;

W^2 is independently selected from a bond, N(R^1), N(R^4), C(R^1)(R^1), C(R^1)(R^4), C(R^4)(R^4), C(O), S, O, S(O), and S(O)$_2$;

W^4 is selected from C(R^1)(R^1), C(R^1)(R^4), C(R^4)(R^4), C(O), S(O), and S(O)$_2$;

W^5 is selected from N, C(R^1), and C(R^4);

s1 is an integer from 1 to 6;

s2 is an integer from 1 to 3;

s3 is an integer from 1 to 3;

each R^1 is independently selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}haloalkyl, C_{3-12}cycloalkyl, -CH_2-C_{3-12}cycloalkyl, C_{1-11}heterocycloalkyl, -CH_2-C_{1-11}heterocycloalkyl, C_{6-12}aryl, -CH_2-C_{6-12}aryl, -CH_2-C_{1-11}heteroaryl, and C_{1-11}heteroaryl, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}haloalkyl, C_{3-12}cycloalkyl, -CH_2-C_{3-12}cycloalkyl, C_{1-11}heterocycloalkyl, -CH_2-C_{1-11}heterocycloalkyl, C_{6-12}aryl, -CH_2-C_{6-12}aryl, -CH_2-C_{1-11}heteroaryl, and C_{1-11}heteroaryl are optionally substituted with one, two, or three R^{20a};

each R^4 is independently selected from hydrogen, halogen, -CN, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, -OR^{12}, -SR^{12}, -N(R^{12})(R^{13}), -C(O)OR^{12}, -OC(O)N(R^{12})(R^{13}), -N(R^{14})C(O)N(R^{12})(R^{13}), -N(R^{14})C(O)OR^{15}, -N(R^{14})S(O)$_2R^{15}$, -C(O)R^{15}, -S(O)R^{15}, -OC(O)R^{15}, -C(O)N(R^{12})(R^{13}), -C(O)C(O)N(R^{12})(R^{13}), -N(R^{14})C(O)R^{15}, -S(O)$_2R^{15}$, -S(O)$_2$N(R^{12})(R^{13})-, S(=O)(=NH)N(R^{12})(R^{13}), -CH_2C(O)N(R^{12})(R^{13}), -CH_2N(R^{14})C(O)R^{15}, -CH_2S(O)$_2R^{15}$, and -CH_2S(O)$_2$N(R^{12})(R^{13}), wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20a};

R^6 is -L^2-R^5 and wherein R^6 is optionally capable of forming a covalent bond with a Ras amino acid;

L^2 is -C(O)-;

R^5 is selected from C_{3-12}cycloalkyl, - C_{1-11}heterocycloalkyl, C_{6-12}aryl, and C_{1-11}heteroaryl, -wherein the C_{3-12}cycloalkyl, C_{1-11}heterocycloalkyl, C_{6-12}aryl, and C_{1-11}heteroaryl are optionally substituted with one, two, or three R^{20k};

R^8 is selected from hydrogen, halogen, -CN, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, -OR^{12}, -SR^{12}, -$N(R^{12})(R^{13})$, -$C(O)OR^{12}$, -$OC(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)OR^{15}$, -$N(R^{14})S(O)_2R^{15}$, -$C(O)R^{15}$, -$S(O)R^{15}$, -$OC(O)R^{15}$, -$C(O)N(R^{12})(R^{13})$, -$C(O)C(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)R^{15}$, -$S(O)_2R^{15}$, -$S(O)_2N(R^{12})(R^{13})$-, $S(=O)(=NH)N(R^{12})(R^{13})$, -$CH_2C(O)N(R^{12})(R^{13})$, -$CH_2N(R^{14})C(O)R^{15}$, -$CH_2S(O)_2R^{15}$, and -$CH_2S(O)_2N(R^{12})(R^{13})$, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20c};

R^{17} is -L^1-R^{19};

L^1 is selected from a bond, C_1-C_4alkyl, C_2-C_4alkenyl, C_2-C_4alkynyl, -O-, -$N(R^{14})$-, -C(O)-, -$N(R^{14})C(O)$-, -$C(O)N(R^{14})$-, -S-, -$S(O)_2$-, -S(O)-, -$S(O)_2N(R^{14})$-, -$S(O)N(R^{14})$-, -$N(R^{14})S(O)$-, -$N(R^{14})S(O)_2$-, -$OCON(R^{14})$-, -$N(R^{14})C(O)O$-, $N(R^{1e})$, $C(O)N(R^{1c})$, $S(O)_2N(R^{1c})$, $S(O)N(R^{1c})$, $C(R^{1f})(R^{1g})O$, $C(R^{1f})(R^{1g})N(R^{1c})$, and $C(R^{1f})(R^{1g})$; wherein the C_1-C_4alkyl, C_2-C_4alkenyl, and C_2-C_4alkynyl are optionally substituted with one, two, or three R^{20i};

R^{1e}, R^{1f}, and R^{1g} are independently selected from hydrogen, halogen, -CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, -OR^{12}, -SR^{12}, -$N(R^{12})(R^{13})$, -$C(O)OR^{12}$, -$OC(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)OR^{15}$, -$N(R^{14})S(O)_2R^{15}$, -$C(O)R^{15}$, -$S(O)R^{15}$, -$OC(O)R^{15}$, -$C(O)N(R^{12})(R^{13})$, -$C(O)C(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)R^{15}$, -$S(O)_2R^{15}$, -$S(O)_2N(R^{12})(R^{13})$-, $S(=O)(=NH)N(R^{12})(R^{13})$, -$CH_2C(O)N(R^{12})(R^{13})$, -$CH_2N(R^{14})C(O)R^{15}$, -$CH_2S(O)_2R^{15}$, and -$CH_2S(O)_2N(R^{12})(R^{13})$, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20i}; or R^{1f} and R^{1g} are joined to form a 4-7 membered heterocycloalkyl ring or a 4-7 membered cycloalkyl ring, wherein the 4-7 membered heterocycloalkyl ring or 4-7 membered cycloalkyl ring are optionally substituted with one, two, or three R^{20i}**;**

R^{1c} is selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20i};

R^{19} is selected from a C_{3-12}cycloalkyl, C_{2-11}heterocycloalkyl, C_{6-12}aryl, and C_{2-12}heteroaryl, wherein the C_{3-12}cycloalkyl, C_{2-11}heterocycloalkyl, C_{6-12}aryl, and C_{2-12}heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R^{1i};

each R^{1i} is independently selected from halogen, oxo, -CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, -OR^{12}, -SR^{12}, -$N(R^{12})(R^{13})$, -$C(O)OR^{12}$, -$OC(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)OR^{15}$, -$N(R^{14})S(O)_2R^{15}$, -$C(O)R^{15}$, -$S(O)R^{15}$, -$OC(O)R^{15}$, -$C(O)N(R^{12})(R^{13})$, -$C(O)C(O)N(R^{12})(R^{13})$, -$N(R^{14})C(O)R^{15}$, -$S(O)_2R^{15}$, -$S(O)_2N(R^{12})(R^{13})$-, $S(=O)(=NH)N(R^{12})(R^{13})$, -$CH_2C(O)N(R^{12})(R^{13})$, -$CH_2N(R^{14})C(O)R^{15}$, -$CH_2S(O)_2R^{15}$, and -$CH_2S(O)_2N(R^{12})(R^{13})$, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20i};

R^{16} is selected from hydrogen, halogen, -CN, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, $-OR^{12}$, $-SR^{12}$, $-N(R^{12})(R^{13})$, $-C(O)OR^{12}$, $-OC(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)OR^{15}$, $-N(R^{14})S(O)_2R^{15}$, $-C(O)R^{15}$, $-S(O)R^{15}$, $-OC(O)R^{15}$, $-C(O)N(R^{12})(R^{13})$, $-C(O)C(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)R^{15}$, $-S(O)_2R^{15}$, $-S(O)_2N(R^{12})(R^{13})$-, $S(=O)(=NH)N(R^{12})(R^{13})$, $-CH_2C(O)N(R^{12})(R^{13})$, $-CH_2N(R^{14})C(O)R^{15}$, $-CH_2S(O)_2R^{15}$, and $-CH_2S(O)_2N(R^{12})(R^{13})$, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20g};

R^2 is halogen, -CN, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, $-OR^{12'}$, $-SR^{12'}$, $-N(R^{12'})(R^{13})$, $-C(O)OR^{12'}$, $-OC(O)N(R^{12'})(R^{13})$, $-N(R^{14})C(O)N(R^{12'})(R^{13})$, $-N(R^{14})C(O)OR^{15}$, $-N(R^{14})S(O)_2R^{15}$, $-C(O)R^{15}$, $-S(O)R^{15}$, $-OC(O)R^{15}$, $-C(O)N(R^{12'})(R^{13})$, $-C(O)C(O)N(R^{12'})(R^{13})$, $-N(R^{14})C(O)R^{15}$, $-S(O)_2R^{15}$, $-S(O)_2N(R^{12'})(R^{13})$-, $S(=O)(=NH)N(R^{12'})(R^{13})$, $-CH_2C(O)N(R^{12'})(R^{13})$, $-CH_2N(R^{14})C(O)R^{15}$, $-CH_2S(O)_2R^{15}$, $-CH_2S(O)_2N(R^{12'})(R^{13})$, $-(C_1\text{-}C_6\text{alkyl})\text{-}R^{12b}$, $-(C_{2-6}\text{alkenyl})\text{-}R^{12b}$, $-(C_{2-6}\text{alkynyl})\text{-}R^{12b}$, $-(C_{3-10}\text{cycloalkyl})\text{-}R^{12b}$, $-(C_{2-9}\text{heterocycloalkyl})\text{-}R^{12b}$, $-(C_{6-10}\text{aryl})\text{-}R^{12b}$, or $-(C_{1-9}\text{heteroaryl})\text{-}R^{12b}$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20d};

R^{12b} is selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-CH_2\text{-}C_{3-10}$cycloalkyl, C_{2-9}heterocycloalkyl, $-CH_2\text{-}C_{2-9}$heterocycloalkyl, C_{6-10}aryl, $-CH_2\text{-}C_{6-10}$aryl, $-CH_2\text{-}C_{1-9}$heteroaryl, and C_{1-9}heteroaryl, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-CH_2\text{-}C_{3-10}$cycloalkyl, C_{2-9}heterocycloalkyl, $-CH_2\text{-}C_{2-9}$heterocycloalkyl, C_{6-10}aryl, $-CH_2\text{-}C_{6-10}$aryl, $-CH_2\text{-}C_{1-9}$heteroaryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20d};

each R^{12} is independently selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-CH_2\text{-}C_{3-10}$cycloalkyl, C_{2-9}heterocycloalkyl, $-CH_2\text{-}C_{2-9}$heterocycloalkyl, C_{6-10}aryl, $-CH_2\text{-}C_{6-10}$aryl, $-CH_2\text{-}C_{1-9}$heteroaryl, and C_{1-9}heteroaryl, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-CH_2\text{-}C_{3-10}$cycloalkyl, C_{2-9}heterocycloalkyl, $-CH_2\text{-}C_{2-9}$heterocycloalkyl, C_{6-10}aryl, $-CH_2\text{-}C_{6-10}$aryl, $-CH_2\text{-}C_{1-9}$heteroaryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20d};

each $R^{12'}$ is independently selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-C(R^{12c})_2\text{-}C_{3-10}$cycloalkyl, C_{2-9}heterocycloalkyl, $-C(R^{12c})_2\text{-}C_{2-9}$heterocycloalkyl, C_{6-10}aryl, $-C(R^{12c})_2\text{-}C_{6-10}$aryl, $-C(R^{12c})_2\text{-}C_{1-9}$heteroaryl, and C_{1-9}heteroaryl, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-C(R^{12c})_2\text{-}C_{3-10}$cycloalkyl, C_{2-9}heterocycloalkyl, $-C(R^{12c})_2\text{-}C_{2-9}$heterocycloalkyl, C_{6-10}aryl, $-C(R^{12c})_2\text{-}C_{6-10}$aryl, $-C(R^{12c})_2\text{-}C_{1-9}$heteroaryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20d};

each R^{12c} is independently selected from hydrogen and R^{20m};

each R^{13} is independently selected from hydrogen, C_{1-6}alkyl, and C_{1-6}haloalkyl; or R^{12} and R^{13}, together with the nitrogen to which they are attached, form a C_{2-9}heterocycloalkyl ring optionally substituted with one, two, or three R^{20e};

each R^{14} is independently selected from hydrogen, C_{1-6}alkyl, and C_{1-6}haloalkyl;

each R^{14a} is independently selected from C_{1-6}alkyl and C_{1-6}haloalkyl;

each R^{15} is independently selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20f};

R^{18} is selected from hydrogen, halogen, -CN, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, $-OR^{12}$, $-SR^{12}$, $-N(R^{12})(R^{13})$, $-C(O)OR^{12}$, $-OC(O)N(R^{12})(R^{13})$, -

$N(R^{14})C(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)OR^{15}$, $-N(R^{14})S(O)_2R^{15}$, $-C(O)R^{15}$, $-S(O)R^{15}$, $-OC(O)R^{15}$, $-C(O)N(R^{12})(R^{13})$, $-C(O)C(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)R^{15}$, $-S(O)_2R^{15}$, $-S(O)_2N(R^{12})(R^{13})$-, $S(=O)(=NH)N(R^{12})(R^{13})$, $-CH_2C(O)N(R^{12})(R^{13})$, $-CH_2N(R^{14})C(O)R^{15}$, $-CH_2S(O)_2R^{15}$, and $-CH_2S(O)_2N(R^{12})(R^{13})$, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20h};

each R^{20a}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, R^{20g}, R^{20h}, R^{20i}, R^{20k}, and R^{20m} is independently selected from halogen, oxo, -CN, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-CH_2$-C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, $-CH_2$-C_{2-9}heterocycloalkyl, C_{6-10}aryl, $-CH_2$-C_{6-10}aryl, $-CH_2$-C_{1-9}heteroaryl, C_{1-9}heteroaryl, $-OR^{21}$, $-SR^{21}$, $-N(R^{22})(R^{23})$, $-C(O)OR^{22}$, $-C(O)N(R^{22})(R^{23})$, $-C(O)C(O)N(R^{22})(R^{23})$, $-OC(O)N(R^{22})(R^{23})$, $-N(R^{24})C(O)N(R^{22})(R^{23})$, $-N(R^{24})C(O)OR^{25}$, $-N(R^{24})C(O)R^{25}$, $-N(R^{24})S(O)_2R^{25}$, $-C(O)R^{25}$, $-S(O)_2R^{25}$, $-S(O)_2N(R^{22})(R^{23})$, $-OCH_2C(O)OR^{22}$, and $-OC(O)R^{25}$; wherein two R^{20k} bonded to the same or adjacent atoms may optionally be joined to form a C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, or C_{1-9}heteroaryl; wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, $-CH_2$-C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, $-CH_2$-C_{2-9}heterocycloalkyl, C_{6-10}aryl, $-CH_2$-C_{6-10}aryl, $-CH_2$-C_{1-9}heteroaryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three groups independently selected from halogen, oxo, -CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6}alkoxy, C_{1-6}haloalkoxy, $-OR^{21}$, $-SR^{21}$, $-N(R^{22})(R^{23})$, $-C(O)OR^{22}$, $-C(O)N(R^{22})(R^{23})$, $-C(O)C(O)N(R^{22})(R^{23})$, $-OC(O)N(R^{22})(R^{23})$, $-N(R^{24})C(O)N(R^{22})(R^{23})$, $-N(R^{24})C(O)OR^{25}$, $-N(R^{24})C(O)R^{25}$, $-N(R^{24})S(O)_2R^{25}$, $-C(O)R^{25}$, $-S(O)_2R^{25}$, $-S(O)_2N(R^{22})(R^{23})$, and $-OC(O)R^{25}$;

each R^{21} is independently selected from H, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl;

each R^{22} is independently selected from H, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl;

each R^{23} is independently selected from H and C_{1-6}alkyl;

each R^{24} is independently selected from H and C_{1-6}alkyl;

each R^{25} is independently selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl; and

$\overset{\text{------}}{=}$ indicates a single or double bond such that all valences are satisfied.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is a 5 or 6 membered partially unsaturated heterocycloalkyl or a 5 or 6 membered heteroaryl, each optionally substituted with one, two or three R^{20k}, wherein the partially unsaturated 5 or 6 membered heterocycloalkyl or 5 or 6 membered heteroaryl comprises one, two, or three ring nitrogen atoms; and each is bonded to L^2 through a ring nitrogen.
3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is a 5 membered heteroaryl optionally substituted with one, two or three R^{20k}, wherein the 5 membered heteroaryl comprises one, two, or three ring nitrogen atoms; and the 5 membered heteroaryl is bonded to L^2 through a ring nitrogen.
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is $C(R^8)$.
5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is N.
6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein

L^7 is a bond.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, wherein R^7 is selected from , , , , , , , , , , , , and ; wherein R^1 and R^4 substituents may be bonded to either spirocyclic ring.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt or solvate thereof, wherein L^1 is a bond.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{19} is: , , , , , , , ,



, or 

;

Q^1, Q^3, and Q^5 are independently selected from N and $C(R^{1d})$;

Q^4 and Q^6 are independently selected from O, S, $C(R^{1a})(R^{1b})$, and $N(R^{1c})$;

X^4, X^5, X^6, X^9, X^{10} are independently selected from $C(R^{1a})$ and N;

X^{13} is selected from a bond, $C(R^{1a})$, N, C(O), $C(R^{1a})(R^{1b})$, $C(O)C(R^{1a})(R^{1b})$, $C(R^{1a})(R^{1b})C(R^{1a})(R^{1b})$, $C(R^{1a})(R^{1b})N(R^{1c})$, and $N(R^{1c})$;

X^{14}, X^{15}, X^{17}, X^{18} are independently selected from C(O), $C(R^{1a})$, N, $C(R^{1a})(R^{1b})$, and $N(R^{1c})$;

X^{16} is selected from C, N, and $C(R^{1a})$;

each R^{1a}, R^{1b}, R^{1d}, and R^{1h} is independently selected from hydrogen, halogen, -CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, $-OR^{12}$, $-SR^{12}$, $-N(R^{12})(R^{13})$, $-C(O)OR^{12}$, $-OC(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)OR^{15}$, $-N(R^{14})S(O)_2R^{15}$, $-C(O)R^{15}$, $-S(O)R^{15}$, $-OC(O)R^{15}$, $-C(O)N(R^{12})(R^{13})$, $-C(O)C(O)N(R^{12})(R^{13})$, $-N(R^{14})C(O)R^{15}$, $-S(O)_2R^{15}$, $-S(O)_2N(R^{12})(R^{13})$-, $S(=O)(=NH)N(R^{12})(R^{13})$, $-CH_2C(O)N(R^{12})(R^{13})$, $-CH_2N(R^{14})C(O)R^{15}$, $-CH_2S(O)_2R^{15}$, and $-CH_2S(O)_2N(R^{12})(R^{13})$, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20i}; or R^{1a} and R^{1b} bonded to the same carbon are joined to form a 3-10 membered heterocycloalkyl ring or a C_{3-10}cycloalkyl ring, wherein the 3-10 membered heterocycloalkyl ring or C_{3-10}cycloalkyl ring are optionally substituted with one, two, or three R^{20i}; or two R^{1a} bonded to adjacent atoms are joined to form a 3-10 membered heterocycloalkyl ring, a C_{6-10}aryl ring, a 5-12 membered heteroaryl ring, or a C_{3-10}cycloalkyl ring, wherein the 3-10 membered heterocycloalkyl ring, C_{6-10}aryl ring, 5-12 membered heteroaryl ring, or C_{3-10}cycloalkyl ring are optionally substituted with one, two, or three R^{20i}; or R^{1h} and one of R^{1a}, R^{1b}, R^{1c}, and R^{1d} bonded to adjacent atoms are joined to form a 3-10 membered heterocycloalkyl ring, a C_{6-10}aryl ring, a 5-12 membered heteroaryl ring, or a C_{3-10}cycloalkyl ring, wherein the 3-10 membered heterocycloalkyl ring, a C_{6-10}aryl ring, a 5-12 membered heteroaryl ring, and C_{3-10}cycloalkyl ring are optionally substituted with one, two, or three R^{20i}; and

each R^{1c} is independently selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl, wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-10}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, and C_{1-9}heteroaryl are optionally substituted with one, two, or three R^{20i}.

10. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt or solvate thereof, wherein

R^{19} is selected from 

, 

,





11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt or solvate thereof, wherein

R^2 is selected from 













12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is selected from , and .

13. A compound selected from , , , , , , , ,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

, and

.

14. A compound selected from

,

,

,

, and



.

15. A pharmaceutical composition comprising a compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
16. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt or solvate thereof, for use in treating cancer in a subject in need thereof.
17. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt or solvate thereof, for use in inhibiting growth of a cell expressing a Ras protein.
18. Use of a compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for use in treating cancer in a subject in need thereof.
19. Use of a compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for use in inhibiting growth of a cell expressing a Ras protein.